AstraZeneca executed a major deal to expand its metabolic and obesity pipeline and outlined large-scale China investments. The company struck a partnership with CSPC that includes an $1.2 billion upfront payment for long-acting, monthly GLP-1/GIP assets and potential milestones that push deal value into the billions, and separately committed more than $15 billion to expand R&D and manufacturing in China through 2030. The CSPC pact gives AstraZeneca access to eight assets and long-acting technologies, including a Phase 1–ready candidate aimed at monthly dosing; CSPC will retain rights in Greater China while AstraZeneca assumes global development and commercialization outside the territory. The China investment plan complements the deal, signaling a coordinated strategy to source peptide innovation from China while building regional capacity. Company statements and filings indicate AstraZeneca views both moves as strategic and complementary: the CSPC transaction accelerates near-term pipeline breadth while the China investments secure long-term R&D and manufacturing scale. Investors and competitors should expect accelerated program progression and broader commercialization plans for next-generation metabolic therapies.